Company Overview and News

 
Will Phillips 66 Roll-Up Its MLP?

14h seekingalpha
The recent FERC decision that MLPs can no longer include an income tax allowance in their cost of service calculation was a bombshell.

 
Pipeline Operators Eliminating MLPs: Victims of FERC Ruling?

2018-05-18 zacks
The May 17, 2018 date is marked important on the calendar for energy infrastructure master limited partnerships (MLPs). This is because major energy companies made headlines on this day as they consolidated their respective pipeline assets. A flurry of merger and acquisition deals hit the energy MLP industry yesterday, mainly in response to the Federal Energy Regulatory Commission (FERC) tax overhaul, announced a couple of months ago to reduce certain benefits for the MLPs.

 
Enbridge To Consolidate Assets In $8.94B Restructuring

2018-05-17 rigzone
May 17 (Reuters) - Pipeline operator Enbridge Inc said on Thursday it would bring its independent units and liquids and gas pipeline assets under a single listed entity as part of a move to streamline its corporate structure.

 
UPDATE 1-Enbridge to consolidate assets in $8.94 bln restructuring

2018-05-17 reuters
May 17 (Reuters) - Pipeline operator Enbridge Inc said on Thursday it would bring its independent units and liquids and gas pipeline assets under a single listed entity as part of a move to streamline its corporate structure.

 
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

2018-05-16 zacks
Chicago, IL – May 16, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include General Dynamics (GD - Free Report) , Enbridge (ENB - Free Report) , CSX Corp. (CSX - Free Report) , Humana (HUM - Free Report) and Vertex (VRTX - Free Report) .

 
Don't Buy L Brands - Cramer's Lightning Round (5/15/18)

2018-05-16 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, May 15.

 
Enbridge Q1 2018 Earnings Results Analysis

2018-05-16 seekingalpha
Enbridge reported very good first quarter 2018 results, showing strong revenue and cash flow growth Y-O-Y.

 
Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares

2018-05-15 cnbc
Bristol-Myers Squibb: "Bristol-Myers right now does not have what we're looking for in terms of that cancer franchise that's going to Merck. I've got to tell you, down here, with a 3 percent yield, it gets attractive. But because of interest rates going higher, I'm going to have to take a pass for the moment."

 
Top Research Reports for General Dynamics, Enbridge & CSX Corporation

2018-05-15 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Enbridge (ENB) and CSX Corp. (CSX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

 
21 Dividend Increases: May 7-11, 2018 (Part 1: Energy, Financials, And Industrials)

2018-05-14 seekingalpha
Part 1 presents dividend increases from the Energy, Financials, and Industrials sectors. Part 2 covers the remaining sectors.

 
Hey, oil giants: Looking to sell renewables? Funds are all ears

2018-05-10 thestar.com.my
NEW YORK: If more oil and gas companies want to follow Enbridge Inc’s lead and sell renewable energy assets, there are plenty of institutional investors ready to pounce.

 
Hey Oil Giants: Looking to Unload Renewables? Funds Are All Ears

2018-05-09 rigzone
(Bloomberg) -- If more oil and gas companies want to follow Enbridge Inc.’s lead and sell renewable energy assets, there are plenty of institutional investors ready to pounce.

 
Energy Infrastructure Earnings Rise With Volumes

2018-05-07 seekingalpha
Last week was a busy week of earnings reports for many sectors, including energy infrastructure. Growing energy sector profitability(is feeding through to higher returns to investors. Over the past month, the Energy Select Sector SPDR ETF (NYSEARCA:XLE) has outperformed the S&P by over 9%. RBN Energy has a good blog post (see "Better - E&P Profits Appear Ready To Take Off This Year After Turning A Corner In 2017") highlighting that the 2017 impairments are unlikely to be repeated and that higher oil prices will drive improved operating margins.

1
SA Stock To Watch: Netflix To The Rescue?

2018-04-14 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

 
The Zacks Analyst Blog Highlights: IBM, Enbridge, ADP, Marathon and United Continental

2018-04-13 zacks
Chicago, IL – April 13, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include IBM (IBM - Free Report) , Enbridge (ENB - Free Report) , ADP (ADP - Free Report) , Marathon Petroleum (MPC - Free Report) and United Continental (UAL - Free Report) .

Related Articles

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...

CUSIP: 847560109